Avandia explored in depth

Avandia, also known as rosiglitazone, the diabetes drug, which has been raked over the coals for the past two months is still available on the market. The British Medical Journal has published a major article on the subject which includes an outlined history and a long list of references. The article will gives you a broad perspective on the issues and the players and the strange mix of money, politics, and medicine involved in the creation and exploitation and slow demise of a blockbuster drug.

from the BMJ by Deborah Cohen

…To date, the FDA and the EMA have decided that the drug (Avandia/rosiglitazone) is safe enough to stay on the market. But the story reflects badly on almost everyone involved: the regulators, the manufacturer, GlaxoSmithKline, and the clinical community. It has also raised a host of questions. Why did the regulators accept such poor evidence on benefit and safety for rosiglitazone? Did GlaxoSmithKline mislead the regulators? Should the drug have been licensed in the first place and should it now be withdrawn? Why haven’t patients in the UK and Europe been made aware of the concerns about rosiglitazone’s effects? And is the current drug regulatory system up to the job?….

much, much more via Rosiglitazone, what went wrong?

    Leave a Reply

    Fill in your details below or click an icon to log in:

    WordPress.com Logo

    You are commenting using your WordPress.com account. Log Out / Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out / Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out / Change )

    Google+ photo

    You are commenting using your Google+ account. Log Out / Change )

    Connecting to %s

%d bloggers like this: